Introduction: Sphingosine-1-phosphate (S1P) is a membrane-derived lysophospholipid signaling molecule implicated in various physiological and pathological processes, such as regulation of the immune, cardiovascular, pulmonary, and nervous systems and theoretical cancer-related risks, through extracellular activation of S1P1-5 receptors.

Areas covered: S1P receptor agonism is a novel strategy for the treatment of UC targeting lymphocyte recirculation, through blockade of lymphocyte egress from lymph nodes. We conducted an extensive literature review on PUBMED on currently available data on molecular aspects of S1P modulation, the mechanisms of action of S1PR agonists (fingolimod, ozanimod, etrasimod, and KRP-203), and their potential efficacy and safety for the treatment of patients with ulcerative colitis.

Expert opinion: Selective S1P modulators have emerged to enlarge the efficacy and safety profile of this class of agents. Phase 3 programs should add the potential body of evidence to prove their benefit for the management of UC patients.

简介：1-磷酸鞘氨醇（S1P）是一种膜来源的溶血磷脂信号分子，通过细胞外活化参与各种生理和病理过程，例如调节免疫，心血管，肺和神经系统以及理论上与癌症相关的风险S1P1-5受体。

覆盖的区域：S1P受体激动是一种通过阻断淋巴结中淋巴细胞流出来治疗靶向UC淋巴细胞再循环的UC新策略。我们对PUBMED进行了广泛的文献综述，涉及有关S1P调节的分子方面，S1PR激动剂（芬戈莫德，奥扎尼莫德，埃曲西莫德和KRP-203）的作用机制及其在治疗患者中的潜在功效和安全性方面的现有数据与溃疡性结肠炎。

专家意见：选择性S1P调节剂已经出现，可以扩大此类药物的功效和安全性。第三阶段的计划应增加潜在的证据，以证明其对UC患者的治疗有益。